anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Lovaza
Trial phase: Phase 4
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking 4 g of Lovaza per day for 6 months.

omega-3-acie ethyl esters: Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
Eligibility criteria:
Inclusion Criteria:

Subjects may be males or non-pregnant, non-lactating females age 18-80 years.
Subjects must have been diagnosed with type 2 diabetes mellitus according to the current ADA criteria.
Triglyceride levels above 149 mg/dL
Minimum of 2 years after diagnosis of type 2 diabetes
Prior to participation in this study, each subject must sign an informed consent document.

Exclusion Criteria:

Presence of type 1 diabetes mellitus (defined as C-peptide < 1 ng/ml or diabetes onset at < 35 years of age in a non-obese patient).
Presence of diabetic retinopathy that is more severe than "background" level.
Presence of diabetic nephropathy, defined by urine dipstick results greater than 300 mg/100 mL for protein (proteinuria).
Presence of clinically significant neuropathy that is clearly of non-diabetic origin, e.g. alcoholic or autoimmune.
Bilateral amputation of lower extremities or foot ulcers involving the great toes. Presence of neuroarthropathy (Charcot deformity) is allowable.
History of major macrovascular events such as myocardial infarction or stroke.
Participation in another clinical trial concurrently or within 30 days prior to entry into this study.
The use of ACE-inhibiting agents or angiotensin receptor blockade therapy (ARB) is allowed but must have been stable for at least 30 days prior to study entry and may not change during the course of the study. This is prudent due to their potential effects on blood flow.
Patients with moderate or severe hepatic insufficiency or abnormalities of liver function defined as any liver enzymes (aspartate aminotransferase,alanine transaminase, alkaline phosphatase) greater than 3 times the upper limit of normal.
Presence of pedal edema.
Presence or history of heart failure New York Heart Association Class II or greater.
Other serious medical conditions that in the opinion of the investigator, would compromise the subject's participation in the study.
Concomitant use of medications known to exacerbate triglyceride levels, such as estrogens.
Intervention: Simvastatin
Trial phase: Phase 4
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Child | Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: All subjects will receive dietary instructions according to NCEP-ATP III by a clinical nutritionist. If LDL-C is still above recommended levels after 3 months of appropriate lifestyle changes, patients will be randomly allocated to open-label simvastatin 40 mg daily
Eligibility criteria:
Inclusion Criteria:

LDL-C levels above those recommended by the National Cholesterol Education
Program Adult Treatment Panel III (NCEP-ATP III) based on each patient risk factors following a 3-month period of lifestyle changes.

Exclusion Criteria:

Triglycerides >500 mg/dL, renal disease (serum creatinine levels >1.6 mg/dL), hypothyroidism [thyroid stimulating hormone (TSH) >5 IU/mL] and liver disease (ALT and/or AST levels >3-fold upper limit of normal in 2 consecutive measurements).
Patients with hypertension will be included in the study if they are on stable medication for at least 3 months and their blood pressure is adequately controlled (no change in their treatment will be made during the study period).
Patients currently taking lipid lowering drugs or having stopped them less than 4 weeks before study entry will be excluded
Intervention: Memantine
Trial phase: Phase 4
ATC code: N06DA52 | N06DA53 | N06DX01
SMILES: CC12CC3CC(C)(C1)CC(N)(C3)C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 7
Group description: memantine : participants will be asked to take memantine (20mg/day) for 16 weeks
Eligibility criteria:
Inclusion Criteria:

presence of subjective memory complaints without objective evidence of impaired cognition
family history of Alzheimer's disease

Exclusion Criteria:

major depression
Parkinson's disease
stroke
seizures
uncontrolled diabetes or hypertension
current benzodiazepine use
substance abuse
contraindication for MRI
contraindications for memantine
Intervention: Morphine
Trial phase: Phase 4
ATC code: A07DA52 | N02AA01 | N02AA51 | N02AG01
SMILES: [H][C@@]12C=C[C@H](O)[C@]3([H])Oc4c(O)ccc5c4[C@]13CCN(C)[C@]2([H])C5
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Four mg (0.4 ml) of EREM will be delivered to the epidural space and flushed with 1 ml of saline

Extended Release Epidural Morphine (EREM): A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
Eligibility criteria:
Inclusion Criteria:

A primary unilateral Birmingham hip arthroplasty
Men and women 18-65 years

Exclusion Criteria:

Refusal of regional anesthesia
Laboratory evidence of coagulopathy (platelet count less than 100,000 cells/microliter of blood, prothrombin time greater than 12.1 seconds, partial thromboplastin time greater than 30 seconds, or international normalized ratio of greater than 1.5)
Allergy to morphine
Obstructive sleep apnea
Body mass index (BMI) greater than 40 kg/m2
Pregnant or lactating
Severe renal or hepatic disease
Intervention: Anidulafungin
Trial phase: Phase 2
ATC code: J02AX06
SMILES: [H][C@@]1([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)c2ccc(-c3ccc(-c4ccc(OCCCCC)cc4)cc3)cc2)C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C1=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 61
Group description: Patient will receive a dose daily for a total of 14 days

anidulafungin: TBA
Eligibility criteria:
Inclusion Criteria:

Adult patients (>18 years old)
In the ICU > 48 hours
Mechanically ventilated (>48 hours)
Grow a Candida spp. on respiratory tract secretion culture (either by Bronchoalveolar Lavage or Endotracheal Aspirate) taken on or between 48 hours before or after the day of their suspicion of respiratory tract infection.

Develop a clinical suspicion of respiratory tract infection while ventilated as defined by the following criteria (as defined previously in our VAP trial)5:

The presence of new, worsening or persistent radiographic features suggestive of pneumonia without another obvious cause AND

The presence of any two of the following:

Fever > 38C (core temperature)
Leukocytosis (>11.0 x109/L) or neutropenia (<3.5 x109/L)
Purulent endotracheal aspirates or change in character of aspirates
Isolation of pathogenic bacteria from endotracheal aspirates
Increasing oxygen requirements

Exclusion Criteria:

Patients not expected to be in ICU for more than 72 hours (due to imminent death, withdrawal of aggressive care or discharge).
Patients with Candida spp. in the blood or another sterile body site.
Patients colonized at other non-pulmonary body site(s) with Candida.
Already being treated with antifungal drugs (because of documented fungal infection, pre-emptive therapy, or prophylaxis).
Allergy to study drugs (Fluconazole or the Echinocandin on formulary at treating institution).
Immunocompromised patients (post-organ transplantation, Acquired Immunodeficiency Syndrome [AIDS], neutropenia [<1000 absolute neutrophils], corticosteroids [>20 mgs/day of prednisone or equivalent for more than 6 months]). These patients are excluded since Candida may be more invasive and these patients are much more likely to require systemic antifungal therapy.
Patients with fulminant liver failure or end stage liver disease (Child's Class C).
Women who are pregnant or lactating.
Enrollment in industry sponsored interventional trial (co-enrollment in other academic studies would be allowed with the proviso that there was no potential interaction between the protocols).
Prior randomization in this study.
Intervention: Aliskiren
Trial phase: Not Applicable
ATC code: C09DX02 | C09XA02 | C09XA52 | C09XA53 | C09XA54
SMILES: COCCCOc1cc(C[C@@H](C[C@H](N)[C@@H](O)C[C@H](C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)ccc1OC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: 300 mg, once daily, for 6 weeks
Eligibility criteria:
Inclusion Criteria:

Individuals >18 years old with type 1 or type 2 diabetes mellitus.

Exclusion Criteria:

Individuals currently taking the maximum dose of an ACE inhibitor or an ARB.
Individuals with a history of a MI, percutaneous coronary interventions, coronary artery bypass graft (CABG) surgery, acute coronary syndromes, recent/on going atrial fibrillation, frequent atrial arrhythmias, frequent ventricular arrhythmias, or acute myocardial ischemia changes.
Individuals whose treatment dosage changes 2 months prior to the study for antihypertensive and antidiabetes medications, and the following medications that may affect the ANS: anti-tuberculosis drugs, nitrofurantoin, metronidazole, chloramphenicol, perhexiline maleate, amiodarone, clofibrate, tricyclic antidepressants, phenytoin, barbiturates, neuroleptic, antiparkinsonism drugs, and nitrated drugs.
Pregnant or lactating females.
Individuals with impaired renal function (i.e., creatinine >1.5 mg/dl), a history of dialysis, nephritic syndrome or renovascular hypertension.
Individuals with potassium levels within 0.5 mmol/L of the upper limit of normal (i.e., hyperkalemia).
Intervention: Simvastatin
Trial phase: Phase 1
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: Male
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 30
Group description: Simvastatin 40 mg tablets once daily for 2 weeks in either Period 1 or Period 2
Eligibility criteria:
Inclusion Criteria:

Participant is a Caucasian (including Hispanic) male
Participant has a maximum waist size of 40 inches
Participant does not currently use any lipid-altering medications
Participant is in good health other than the diagnosis of dyslipidemia

Exclusion Criteria:

Participant has had stomach ulcers within the last 3 months
Participant has had a heart attack in the last 6 months or has angina
Participant has chronic heart failure
Participant has a history of stroke, seizures, or major neurological disorder
Participant has a history of cancer
Participant has a gastrointestinal condition that affects bowel movements
Participant has type 1 or 2 diabetes
Intervention: Basaglar
Trial phase: Phase 3
SMILES: CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(Cc3c[nH]cn3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(Cc3c[nH]cn3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccccc3)C(=O)NC(Cc3ccc(O)cc3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NCC(=O)O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(Cc3ccc(O)cc3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 212
Group description: Subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
Eligibility criteria:
Inclusion Criteria:

present with type 2 diabetes mellitus
HbA1c between 7.1% and 11.0% inclusive
body mass index (BMI) of >18kg/m2 and <35kg/m2, inclusive
treated with a stable dose regimen of either of biguanide (BG) alone, BG + thiazolidinedione (TZD), BG + sulfonylurea (SU), or BG + TZD + SU for 90 days prior to study start

Exclusion Criteria:

Have received chronic (>14 consecutive days) systemic adrenocorticosteroid therapy by oral, intravenous, or intramuscular route or intraarticular steroid injection within 4 weeks prior to study start.
Have been treated with drugs that promote weight loss within 90 days prior to study start.
Have been treated with drugs that directly affect gastrointestinal motility for > 21 consecutive days within 90 days prior to study start.
Have had prior exposure to exenatide BID or QW or participated in the clinical trial of exenatide BID or QW (including the case that the study drug was not administered).
Have been treated for >2 consecutive weeks with any of the following excluded medications within 90 days prior to study start: Insulin, Dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 analogs
Have received treatment within 30 days prior to study start drug that has not received regulatory approval for any indication.
Are currently enrolled in any other clinical study or participated in and completed the clinical study within 30 days prior to study start.
Have donated blood within 30 days prior to study start.
Intervention: Lovaza
Trial phase: Phase 3
SMILES: CCC=CCC=CCC=CCC=CCC=CCC=CCCC(=O)OCC.CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 76
Group description: omega-3-acid ethyl esters (Four 1-gram capsules daily)
Eligibility criteria:
Inclusion Criteria:

Diagnosis of HTN
Hispanic or Non-Hispanic White
Age > 18

One additional CVD risk factor

Age > 55 for males or >65 for females
DM
Dyslipidemia O TC >220 or O LDL >130 or O on statin therapy
Current smoker
Chronic kidney disease defined as GFR <60 ml/min/1.72m2
BMI > 30 kg/m2
Positive microalbuminuria -Able to sign consent form and willing to complete 12-month follow- up period.

Exclusion criteria used for SA3/4 will also apply for Aim 4.3. These include factors rendering assessment of endothelial function unreliable, such as:

Clinically manifest CVD (including angina, myocardial infarction, surgical or percutaneous coronary revascularization, stroke, cerebrovascular revascularization, peripheral vascular disease, heart failure, or valvular heart disease
Electrocardiographic evidence of prior myocardial infarction
Known valvular heart disease of at least moderate severity
Known left ventricular systolic dysfunction (LVEF < 0.50)
End-stage renal disease
History of inflammatory disease or vasculitis (including rheumatoid arthritis, systemic lupus erythematosis, Raynaud phenomenon, or other connective tissue disease/vasculitides)
Corticosteroid therapy
Active substance abuse
Projected life-expectancy <12 months due to comorbid condition
Plans to move away from the Denver area within 12 months
Previous trauma or surgery of the brachial artery
Upper arm circumference exceeding 42 cm.

Additional exclusion criteria for participation in Aim 4.3 include:

Pregnancy or breast-feeding
Known sensitivity or allergy to fish
Known sensitivity or allergy to omega-3 fatty acid supplements
Taking omega-3 fatty acid supplements in the last 2 weeks- may participate after 2 week washout
Triglycerides > 500 mg/dL.
Alanine aminotransferase (ALT) levels above 3x upper limit of normal
Not a good candidate for participation based on the opinion of the investigators.
Current therapy with a fibric acid derivative
Intervention: SODIUM CHLORIDE
Trial phase: Phase 2
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Randomized patients in the drusen or the GA cohort will receive placebo saline infusions as a comparator

Saline: Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).

Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.

Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months.
Eligibility criteria:
Inclusion Criteria:

Ability to provide written informed consent and comply with study assessments for the full duration of the study
Age > 50 years
In the study eye(s), the presence of non-exudative AMD documented by fundus photography, autofluorescence, fluorescein angiography, and spectral domain OCT.
Visual acuity of 20/63 or better (BCVA score of at least 59 letters) as measured on an ETDRS chart.
Able and willing to comply with study procedures.

Exclusion Criteria:

Visual acuity worse than 20/63
Any history of choroidal neovascularization in the study eye
Unresolved meningococcal disease.
Confounding ocular conditions such as amblyopia; aphakia; myopia requiring >6 diopters of correction; pigment epithelial detachment; uncontrolled glaucoma (intraocular pressure ≥ 25 mmHg despite treatment with anti-glaucoma medication); steroid-induced ocular hypertension; retinal inflammatory disease; central serous choroidopathy; prior or current retinal detachment; macular edema; cystic lesion (individual cysts or cystoid macular edema); ocular herpes simplex virus; severe non-proliferative or worse diabetic retinopathy; anterior ischemic optic neuropathy; RPE tear involving the macula; pseudovitelliform macular degeneration; vitreo-retinal traction maculopathy; vitreous hemorrhage, history of or current rhegmatogenous retinal detachment or macular hole; uveitis; diffuse choroidal atrophy; optic atrophy (as evidenced by pallor); intraocular inflammation; ocular or periocular infection; moderate or worse dry eye syndrome; clinically significant cataract or opacification of the posterior capsule which, in the Investigator's opinion, would progress during the course of the study and could affect central vision; other ocular conditions that the Investigator believes may be a confounding factor in this study
Refusal to be vaccinated against Neisseria meningitides or an active Neisseria meningitides infection
Intervention: Zolpidem
Trial phase: Not Applicable
ATC code: N05CF02
SMILES: Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: Participants randomized to the Intervention group will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women > or = 65 years). For the purposes of this double-blind trial, zolpidem (e.g., Roxane Laboratories) and placebo (sugar) pills will be placed without filler inside two-piece gelatin capsules (DBcaps, Capsugel) and packaged by the Investigational Drug Service (IDS) of the University of Pittsburgh Cancer Institute.
Eligibility criteria:
Inclusion Criteria:

be women at least 18 years old
have clinical indications of primary endometrioid adenocarcinoma of the endometrium
be scheduled for staging surgery by laparotomy under standardized protocols
have the ability to communicate in English sufficient for completion of study materials
have no neuromuscular/ movement disorders (for actigraphy purposes)
have no uncontrolled medical, sleep, endocrine or psychiatric illness (as determined by their attending physician as part of clinical care)
have no ongoing use of medication known to affect sleep or wake function (e.g., hypnotics, benzodiazepines, antidepressants, anxiolytics, antipsychotics, decongestants, sedating antihistamines, beta blockers, corticosteroids)

Exclusion Criteria:

have a history of previous or concomitant cancer
have an estimated life expectancy of < 6 months
will be admitted to the hospital prior to the day of surgery
are unable to complete study measures
are unable to provide meaningful informed consent
Intervention: Sitagliptin
Trial phase: Phase 4
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 1
Group description: sitagliptin 100 mg daily

Sitagliptin: Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
Eligibility criteria:
Inclusion Criteria:

Recipient of a kidney transplant at UNMC, including cadaveric or living donor transplant.

Exclusion Criteria:

A previous diagnosis of diabetes or previous criteria for diabetes, according to the American Diabetes Association, not previously recognized as diabetes.
Simultaneous transplant of another solid organ, such liver or heart.
Patient unable to take oral medication.
Patient unable to give informed consent.
Hypersensitivity to sitagliptin.
Intervention: Tenofovir
Trial phase: Phase 2
SMILES: C[C@H](Cn1cnc2c(N)ncnc21)OCP(=O)(O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 24
Group description: FTC/TDF (200/300 mg) FDC tablet administered orally once daily for up to 240 weeks
Eligibility criteria:
Key Inclusion Criteria:

Complete all end of study visit procedures and pharmacokinetic (PK) substudy (if applicable) for the GS US 203 0107 study.
A negative pregnancy test is required for female individuals at the end of study visit for GS US 203 0107 (unless surgically sterile or greater than two years post-menopausal).
All sexually active female individuals who are not post menopausal, or surgically sterile and are of childbearing potential must agree to use a highly effective method of contraception during heterosexual intercourse throughout the study.
Male individuals who are sexually active are required to use barrier contraception (condom with spermicide) during heterosexual intercourse through to study completion.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Intervention: Amphotericin B
Trial phase: Phase 4
ATC code: A01AB04 | A07AA07 | G01AA03 | J02AA01
SMILES: CC1C=CC=CC=CC=CC=CC=CC=CC(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 13
Group description: Intestinal failure and other patients with poor IV access and central line fungal-related infections

After enrollment, antifungal therapy will be instituted consisting of both IV systemic and antifungal lock therapy. Systemic therapy will be Ambisome administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing up to 2.3 ml (maximum catheter size) of concentrated Ambisome (2 mg/ml) into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days.
Eligibility criteria:
Inclusion Criteria:

Patients with intestinal insufficiency and central venous access.
Culture positive fungal-related CRBSI.
Females of childbearing potential will be eligible for the study.
Ambisome carries a category B Pregnancy Risk Factor. Since this is a minimal pregnancy risk category, no special precautions will be taken to determine that the patient is not pregnant.
HIV serostatus will not be determined for the purpose of participating in this study.

Exclusion Criteria:

Patients less than 30 days of age
Patients greater than 21 years of age